Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings | Zendy

Daniel G. Hackam | Zendy

Open Access

Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings

Author(s) -

Daniel G. Hackam

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.559054

Subject(s) - medicine , secondary prevention , angiotensin receptor blockers , stroke (engine) , primary prevention , angiotensin ii , intensive care medicine , pharmacology , receptor , renin–angiotensin system , blood pressure , disease , mechanical engineering , engineering

Geoffrey A. Donnan MD, FRACP Stephen M. Davis MD, FRACP Section Editors: Each year, stroke is responsible for 5.5 million deaths worldwide and the loss of >49 million disability-adjusted life-years. Interventions that effectively and efficiently prevent stroke therefore exert major economic, societal, and personal impact. An important modifiable risk factor for stroke is blood pressure, abnormal levels of which account for 54% of the worldwide burden of cerebrovascular disease.1 Unequivocal evidence supports blood pressure-lowering for preventing stroke both in primary and secondary prevention settings.Although most systematic reviews, including the series of analyses produced by the Blood Pressure Lowering Treatment Trialists’ Collaboration, suggest that all major classes of …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research